Full Press Release Details
Releases Statement on Healive Vaccine Suspension
December 2, 7:00 am ET
Dec. 2 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Alternext US: SVA), a
leading provider of vaccines in China, announced today that, the Health Services
Bureau of Fengtai District in the City of Beijing suspended the use of 83 doses
of inactivated hepatitis A vaccine Healive , following a report of the death of
a minor in the Fengtai District on November 27, 2008, which coincided with the
administration of the vaccine two days prior.
suspended vaccine was part of lot 2008052105 that passed the routine government
inspection in July 2008. To date, 19,850 doses vaccines from the lot have been
distributed. According to data released by the Center for Adverse Drug Reaction
Monitoring of Beijing, there is no other reported adverse reaction to the lot to
date. Sinovac has not received, and is not aware of, similar notice of
suspension from any other district in Beijing where the lot has been distributed
or any other part of China where other lots of the Healive vaccine have been
distributed. On November 29, 2008, the Beijing Drug Administration and Drug
Administration of Haidian District of City of Beijing conducted a joint
administrative investigation that included an inspection of the company's
manufacturing site and review of its manufacturing, inspection and sales
processes, and concluded in a written report that no abnormality was
has full confidence in the quality of its products. It will continue to
cooperate with government agencies in their investigation of the incident and
will provide an update once the investigation is completed.
Biotech Ltd. is a China-based biopharmaceutical company that focuses on the
research, development, manufacture and commercialization of vaccines that
protect against human infectious diseases. Sinovac's commercialized vaccines
include Healive (hepatitis A), Bilive (combined hepatitis A and B), Anflu
(influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal
Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional
information about Sinovac is available on its website, http://www.sinovac.com
. To be added to our distribution list, please email: info@sinovac.com.
more information, please contact:
Tel: +86-10-8289-0088
Fax: +86-10-6296-6910
Carrington / Janine McCargo
Tel: +1-646-536-7017/7033